The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 26, 2018

Filed:

Sep. 14, 2016
Applicant:

Astellas Pharma Inc., Chuo-ku, Tokyo, JP;

Inventors:

Atsushi Suzuki, Tokyo, JP;

Makoto Asaumi, Tokyo, JP;

Kazuhisa Tsunoyama, Tokyo, JP;

Kouichi Nishimura, Tokyo, JP;

Akifumi Morinaka, Tokyo, JP;

Tomohiro Yamauchi, Tokyo, JP;

Masayasu Yoshino, Tokyo, JP;

Hiroaki Yoshizaki, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); G01N 33/574 (2006.01); G01N 33/74 (2006.01); C12Q 1/68 (2018.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); C07K 14/71 (2006.01); C07K 14/47 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/4439 (2013.01); A61K 31/496 (2013.01); C07K 14/47 (2013.01); C07K 14/71 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); G01N 33/57423 (2013.01); G01N 33/74 (2013.01); C07K 2319/00 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/50 (2013.01);
Abstract

The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.


Find Patent Forward Citations

Loading…